Finzati - Logo
WAT logo

Waters Corporation

WAT • Medical - Diagnostics & Research
$442.83
— 0.00 (0.00%)
Current price
EarningsLatest report: Jul 4, 2026
BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.
Market Cap
$43.44B
Growth
10.0%
Cash Flow
5/5
Trend
Stable
Evidence
Stable or improving margins · 20.3%Positive free cash flow · 9.07Consistent free cash flow · 5/5Manageable debt level · 0.58Healthy liquidity · 1.73
Financial data as of: Jul 4, 2026, 12:00 AM UTCLast earnings update: Jul 4, 2026, 12:00 AM UTCLast profile update: Aug 13, 2026, 12:05 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$442.83
Change0.00%
Shares Out98.20M
Market Cap$43.44B
Enterprise Value$42.90B
52W Range282.77 - 416.62
Beta1.19
P/E261.46
P/S9.35
P/B2.86
P/FCF109.57
EV/Sales9.24

Investment DNA

How strong this company looks for long-term investors

71
out of 100
Business Quality
Margins, moat, returns
85/100
Financial Strength
Debt, cash, stability
87/100
Growth Potential
Revenue and expansion
45/100
Price Attractiveness
Cheap or expensive today
31/100
Why this score▼
Stable or improving margins · 20.3%Positive free cash flow · 9.07Consistent free cash flow · 5/5Manageable debt level · 0.58Healthy liquidity · 1.73Expensive earnings multiple · 35.17

Analyst view

Analyst sentiment and price target

WAT
Analyst sentiment
Based on 37 analyst votes · 2026-10-20
73/100
Bullish
Bullish
19
Hold
16
Bearish
2
Price Target
2026-08-13
Low
$375.00
Mean
$420.64
Median
$420.00
High
$475.00

Company Overview

IPO: 11/17/1995
Industry: Medical - Diagnostics & Research
P/B i: 2.86
Debt / Equity i: 0.58
Operating Margin: 28.22%
Net Margin: 20.30%
ROE i: -
ROIC: -

Financial Health

Score17 / 20
Debt / Equity: 0.58
Current Ratio: 1.73
Quick Ratio: 1.27
Status: Strong

Insider Transactions

Recent executive and insider activity

KUEBLER CHRISTOPHER A
Transaction: 08/06/2026
SELL
Change
-3,626
Price
$136.43
Filing
08/07/2026
Type
SELL
KUEBLER CHRISTOPHER A
Transaction: 08/06/2026
SELL
Change
-3,626
Price
$397.94
Filing
08/07/2026
Type
SELL
Jiang Wei
Transaction: 06/30/2026
BUY
Change
—
Price
Not reported
Filing
07/02/2026
Type
BUY